TransMedics Group (NASDAQ:TMDX) Shares Break Above 50-Day Moving Average – Here’s Why

TransMedics Group, Inc. (NASDAQ:TMDX) shares crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $79.61 and traded as high as $88.44. TransMedics Group shares last traded at $88.24, with a volume of 3,950,703 shares trading hands.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

Analysts Set New Price Targets

Several analysts have weighed in on the company. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. TD Cowen reissued a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Zacks Research upgraded TransMedics Group from a “strong sell” rating to a “hold” rating in a research note on Monday, November 2nd. Piper Sandler restated an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Finally, UBS Group dropped their price target on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $118.60.

TransMedics Group Trading Up 27.9%

The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The company has a market cap of $3.05 billion, a P/E ratio of 23.91, a price-to-earnings-growth ratio of 1.21 and a beta of 2.14. The stock has a 50-day moving average of $79.61 and a two-hundred day moving average of $93.17.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a return on equity of 13.67% and a net margin of 19.85%. The business had revenue of $203.01 million during the quarter, compared to analysts’ expectations of $178.06 million. During the same quarter in the previous year, the business earned $0.66 earnings per share. The firm’s quarterly revenue was up 41.1% compared to the same quarter last year. On average, equities research analysts predict that TransMedics Group, Inc. will post 1.50 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of the stock in a transaction dated Friday, September 11th. The stock was purchased at an average price of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Several institutional investors have recently bought and sold shares of TMDX. Silvant Capital Management LLC purchased a new position in TransMedics Group in the second quarter worth about $26,000. Ascentis Independent Advisors purchased a new stake in shares of TransMedics Group during the first quarter valued at approximately $30,000. State of Wyoming purchased a new stake in shares of TransMedics Group during the second quarter valued at approximately $31,000. Ancora Advisors LLC purchased a new stake in shares of TransMedics Group during the second quarter valued at approximately $33,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of TransMedics Group during the second quarter valued at approximately $55,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.